FibroGen, Inc. — Q1 2015 Form 10-Q
Issuer note: The filing identifies FibroGen, Inc., not Kyntra Bio, Inc. It covers the quarter ended March 31, 2015; filed May 12, 2015. Financial amounts below are in U.S. dollars.
Business context and reporting period
FibroGen is a clinical-stage biopharmaceutical company with no product-sales revenue to date. Its lead candidate, roxadustat, was in Phase 3 development for anemia in chronic kidney disease (CKD); FG-3019 was in Phase 2 for idiopathic pulmonary fibrosis, pancreatic cancer and liver fibrosis. Roxadustat development is conducted with Astellas and AstraZeneca.
Key financial metrics
| Metric | Q1 2015 | Q1 2014 / comparator |
|---|---|---|
| Revenue | $16.3 million | $17.9 million |
| Operating expenses | $61.0 million | $32.1 million |
| Operating loss | $44.7 million | $14.2 million |
| Net loss | $46.4 million | $16.2 million |
| Net loss per share, basic and diluted | $0.78 | $1.23 |
| Cash used in operating activities | $42.2 million | $15.5 million |
- At March 31, 2015, cash and cash equivalents were $128.4 million, short- and long-term investments were $153.8 million, and receivables were $7.0 million. Management reported these combined resources as $289.2 million, excluding restricted cash. Cash and cash equivalents plus investments totaled $282.2 million.
- Current assets were $155.4 million and current liabilities $54.0 million. Total liabilities were $231.7 million. The balance sheet included $96.9 million of long-term lease financing obligations and $14.8 million of product development obligations; the filing does not present conventional borrowings as a separate debt balance.
- Operating loss was about 275% of revenue in Q1 2015, versus about 79% in Q1 2014. Gross margin is not a meaningful reported measure for this development-stage business.
Changes versus the prior comparable period
- Revenue declined 9% to $16.3 million. License and milestone revenue fell 22%, primarily because a portion of AstraZeneca’s $12.0 million China payment had been received in March 2014; collaboration-services revenue rose 50%, mainly with higher reimbursable development costs.
- Research and development expense nearly doubled, rising $24.9 million to $50.5 million. The filing attributes the increase chiefly to roxadustat Phase 3 and FG-3019 Phase 2 trial and drug-development costs, plus increased employee costs.
- General and administrative expense increased 63% to $10.5 million, reflecting additional public-company headcount, stock compensation and legal costs.
- Net loss widened by $30.1 million. Loss per share was lower than in 2014 because weighted-average shares rose substantially after the November 2014 IPO; the periods’ per-share figures are therefore not directly comparable without accounting for the share-count change.
- Cash and cash equivalents fell $37.1 million during the quarter, compared with a $3.4 million decrease in Q1 2014. Stock-based compensation was $6.4 million versus $0.8 million a year earlier.
Outlook, commentary and key risks
- Management said existing cash, investments and expected collaboration payments should fund working capital and capital needs for at least the next 12 months, while cautioning that spending or collaboration changes could shorten the runway. It expects continued losses and substantial development spending.
- Management anticipated U.S. roxadustat approval filing in 2018 and China filing in 2016. These are expectations, not guarantees; the filing emphasizes clinical, regulatory, enrollment, safety and manufacturing uncertainties.
- In May 2015, FibroGen earned a $15.0 million AstraZeneca U.S./Rest-of-World development milestone after finalizing two audited carcinogenicity study reports. It also expected to receive $120.0 million in non-contingent AstraZeneca license payments in Q2 2015.
- Roxadustat’s Phase 3 program was expected to enroll approximately 7,000–8,000 patients worldwide. Identified uncertainties include cardiovascular safety endpoints, possible statin interactions, and whether Phase 2 results will hold in larger trials.
- FibroGen depends substantially on Astellas and AstraZeneca for roxadustat funding and development. Other risks include competition, partner termination or disagreement, China regulatory and operating uncertainties, and reliance on third-party manufacturers. The company reported no material legal proceedings and said disclosure controls were effective.
Investor verification priorities
- Confirm the issuer: the supplied filing is for FibroGen, Inc.; it does not identify Kyntra Bio, Inc.
- Track receipt and accounting treatment of the expected $120 million payment and earned $15 million milestone, including whether additional milestones are achieved.
- Assess cash burn, collaboration funding and the stated 12-month liquidity outlook against continued trial spending and the $42.2 million quarterly operating cash use.
- Verify roxadustat Phase 3 progress, safety findings, enrollment and regulatory timelines, along with FG-3019 trial progress.
- Review the disclosed post-IPO share-sale overhang: the filing said 82% of shares outstanding were restricted under lock-up or market stand-off arrangements but could become eligible for sale beginning May 13, 2015, subject to applicable restrictions.